

Testing for DPD deficiency

Phenotype and/or genotype testing prior to the initiation of treatment with Capecitabine Teva/Xeloda is recommended despite uncertainties regarding optimal pre-treatment testing methodologies. Consideration should be given to applicable clinical guidelines.

Impaired kidney function can lead to increased blood uracil levels with risk for misdiagnosis of DPD deficiency in patients with moderate renal impairment. Capecitabine is contraindicated in patients with severe renal impairment (see section 4.3).

[...]

Phenotypic characterisation of DPD deficiency

[...]

A blood uracil level ≥ 150 ng/ml should be considered indicative of complete DPD deficiency and associated with a risk for life-threatening or fatal fluoropyrimidine toxicity. Blood uracil levels should be interpreted with caution in patients with impaired kidney function (see 'Testing for DPD deficiency' above).

[...]

העלון לרופא נשלח לפרסום במאגר התרופות שבאתר האינטרנט של משרד הבריאות,

<https://israeldrugs.health.gov.il>